The only published account of restarting at the old dose ends in hospital on day one. A patient who had tolerated semaglutide 2.4 mg for roughly a year stopped for five weeks and resumed at the same dose [1]. Within 24 hours she had severe vomiting, diarrhea and significant electrolyte abnormalities. That is a single case and it is the whole published record of that specific sequence.
Gastrointestinal side effects on these drugs are usually a dose-escalation problem, which is why most of what is written about them concerns the first few months. This case is about the other moment nobody plans for: coming back after a gap — the one the stop-or-continue framing leaves out entirely.
What happened
The patient had obesity, hypertension, high cholesterol and anxiety. She had been on semaglutide 2.4 mg for roughly a year, with good tolerance and successful weight loss. [1] The treatment was interrupted for five weeks during Ramadan.
She restarted at the dose she had been on. Within a day she had severe nausea, vomiting and diarrhea, and laboratory testing found significant electrolyte abnormalities. Severe gastrointestinal intolerance needing hospitalization is described in the literature as rare.
What the gap costs while it lasts
A break is not a neutral pause. Pooled across six studies and 1,776 people who stopped semaglutide or tirzepatide, weight returned at 1.04 kg a month [3]. The 95% credible interval runs 0.80 to 1.29, after an average loss of 15.35 kg. Observed follow-up ran from 4 to 52 weeks.
So a five-week gap is roughly a kilogram and a quarter on those point estimates, and a rate is something a buyer can price. The restart question and the regain question are the same question seen from two ends.
The alternative to a full stop
A randomized maintenance trial tested the middle option directly. All 441 participants spent 60 weeks on tirzepatide, then were randomized to continue, halve the dose, or stop [2]. Weight at week 112 sat 21.9% below baseline on the full dose, 16.6% at 5 mg, and 9.9% on placebo.
Rescue therapy was needed by 8% of the full-dose group, 25% of the halved group and 67% of those switched to placebo. Halving held most of the benefit. So a reduced maintenance dose is the option with evidence behind it where a gap is a budget decision rather than a clinical one.
Why this belongs on a price site
Because gaps mostly are not medical decisions. A prepay term ends and the next one has not been bought. A shipment is late. A seller runs out of a strength. A month arrives where the subscription is the thing that gets cut.
Each of those is a treatment interruption with a restart attached to it. The terms a seller attaches to its price decide how likely one is. That is a real cost of a cheap prepay nobody puts on the page. The more familiar one is that most people stop inside a year anyway.
How a gap even gets counted varies by whoever is counting it. Persistence definitions use refill windows of different lengths [4]. The same patient reads as continuous in one study and lapsed in another, so the threshold is a choice rather than a fact.
What this page will not tell you
How to restart. There is guidance on re-escalating after an interruption. It depends on the product and how long the gap was, and it is not this desk’s to give.
What is safe to say is narrower. Mention a gap to whoever prescribes the drug before the next injection, rather than treating the restart as picking up where you left off. The dose is the variable everything else on this market is priced around. That is why the dose people stay on is worth knowing before a gap ever happens.
How much weight one case carries
Very little, as evidence. One patient cannot establish a rate, and severe cases like this one are reported precisely because they are unusual.
It carries more as a description. The sequence is long tolerance, short gap, full-dose restart, immediate trouble. It is common enough on this market that most readers will recognize at least the first three steps.